Innovative Business Models

For medical innovation to thrive and cope with the challenges facing the healthcare ecosystem, both healthcare service providers and life science companies need to focus their attention on innovative business models emphasising collaboration amongst healthcare market and non-market players.

What’s next?

  • Which business models and entrepreneurial financing methods are needed by start-up life science companies to survive the valley of death and thrive in their science-business?

  • Which innovative business models are needed to co-design and build converging life sciences and technology-based health solution technologies to market?

  • Which collaborative process and organisational mechanisms amongst life science and technology companies are needed to make translational medicine happen?

  • As a healthcare service provider or as a life sciences company: are you geared up for the move towards targeted medicine, the empowered patient, and for the move from cure to care?

  • As an innovative medical technology company: is your non-market strategy sufficiently collaborative with the health regulator and payer?

  • Do you have a health system perspective transcending individual healthcare agents when designing health technology-based solutions?


Walter Van Dyck
Associate Professor of Technology & Innovation Management and Partner at Vlerick Business School where he chairs the Technology & Operations Management Area. Walter obtained a Doctorate of Business Administration with the highest honours from Cranfield University, School of Management (UK), an MA from the Royal Military Academy Brussels and an MBA from Vlerick. Prior to joining academia, he was a Director in the life sciences practice of PricewaterhouseCoopers and IBM, predominantly active in the fields of R&D and innovation management.




Innovative Business Models

Accreditations
& Rankings

Equis Association of MBAs AACSB Financial Times